3.70
-0.02 (-0.54%)
| Previous Close | 3.72 |
| Open | 3.75 |
| Volume | 152,276 |
| Avg. Volume (3M) | 258,867 |
| Market Cap | 244,468,592 |
| Price / Sales | 20.69 |
| Price / Book | 2.73 |
| 52 Weeks Range |
| Operating Margin (TTM) | -17,082.39% |
| Diluted EPS (TTM) | -0.740 |
| Quarterly Revenue Growth (YOY) | -87.30% |
| Total Debt/Equity (MRQ) | 36.60% |
| Current Ratio (MRQ) | 2.30 |
| Operating Cash Flow (TTM) | -29.70 M |
| Levered Free Cash Flow (TTM) | -18.87 M |
| Return on Assets (TTM) | -21.92% |
| Return on Equity (TTM) | -55.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Adagene Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 4.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -3.0 |
| Average | 0.00 |
|
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 4.70% |
| % Held by Institutions | 33.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deerfield Management Company, L.P. | 30 Jun 2026 | 2,666,666 |
| Hsg Holding Ltd | 30 Jun 2026 | 1,343,364 |
| Dauntless Investment Group, Llc | 30 Jun 2026 | 537,230 |
| Exome Asset Management Llc | 30 Jun 2026 | 488,293 |
| Birchview Capital, Lp | 30 Jun 2026 | 240,000 |
| Moneta Group Investment Advisors Llc | 30 Jun 2026 | 200,000 |
| Mill Creek Capital Advisors, Llc | 31 Mar 2026 | 199,610 |
| Pathstone Holdings, Llc | 30 Jun 2026 | 199,610 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LUO PETER | 3.94 | - | 23,245 | 84,776 |
| Aggregate Net Quantity | 23,245 | |||
| Aggregate Net Value ($) | 84,776 | |||
| Aggregate Avg. Buy ($) | 3.94 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LUO PETER | Officer | 05 Aug 2026 | Buy (+) | 279 | 4.23 | 1,180 |
| LUO PETER | Officer | 04 Aug 2026 | Buy (+) | 22,966 | 3.64 | 83,596 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |